Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method
With the coming Oil & Gas Asia Exhibition in Pakistan, ECHEMI rolls out a new bulk purchasing activity for its new and old customers. This activity will be valid before March 16 when the exhibition come to the end. The more you buy, the more money you will save.
How to join this bulk purchasing?
You can enjoy the most favorable prices via three steps:
First, you should come to the home page of ECHEMI, then you can see the the following page:
Second, input your demand and submit the inquiry.
Third, ECHEMI will give you a reply within 1 working day after receiving your inquiry.
Opportunity knocks but once! Come on, seize this opportunity right now!
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Lilly Bets Bigger on China
-
Rising API Costs Threaten Drug Prices
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
Novo Nordisk Faces a Compliance Test
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Vertex Shares Plunge 14.4 Percent After Pain Drug Trial Misses Key Target and Study Halt
-
Syndax Q2 Net Loss Widens to $71.8 Million Despite 43 Percent Revenue Surge and New Drug Momentum
-
Sandoz Set to Slash Canadian Weight-loss Drug Prices by Up to 70 Percent Generics Could Expand Patient Access
-
Pfizer Lifts 2025 Profit Forecast After Q2 Earnings Beat Sales Hit $14.65 Billion Shares Jump 2.8 Percent
Recommend Reading
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
January Ethylene Glycol Stabilizes and Stops Falling, Enters Range-bound Oscillation
-
Steel in the Hourglass: Germany’s “Protect-Steel” Proposal and the Green Calculation Behind It
-
Ethanol Market Prices Slightly Decline
-
Potassium Sorbate in Food: Safety, Uses, and Alternatives
-
This Week's Sodium Metabisulfite Prices Remain Stable (1.12-1.16) in China